Back to programme
Wed 22 Oct 25 11:00-12:30
SCS
Future vaccination strategies - PART 2 SCS09
Auditorium 1 - Plenary Hall
Chairs
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Read more
Marios KOUTSAKOS
University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus
    To be confirmed
  2. Breast milk-derived secretory IgA provides broad protection against influenza A virus
    To be confirmed
  3. Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis
    Nancy H. L. LEUNGThe University of Hong Kong, Hong Kong SAR China
  4. Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults
    To be confirmed
  5. Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes
    To be confirmed
  6. Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities
    To be confirmed